Characterization of Extracellular Polymeric Substances (Eps) Produced by \u3ci\u3eCloacibacterium normanense\u3c/i\u3e Isolated from Wastewater Sludge for Sludge Settling and Dewatering

In this study, extracellular polymeric substances (EPSs) producing strain was isolated from municipal wastewater sludge (MWWS). Growth profile and the EPS production by Cloacibacterium normanense using wastewater sludge as raw material in shake flask fermentation for 96 h were investigated. The highest concentration of S-EPS (13.0 ± 0.8 g/L) and C-EPS (0.3 ± 0.1 g/L) were attained at 48 h of fermentation. S-EPS revealed higher flocculation activity (94.2%) and dewaterability (59.9%) than other types of EPS in kaolin suspension. The dewaterability of MWWS with 2 g suspended solids (SS)/L was improved by 37.6% using 0.02 ± 0.01 g/L of S-EPS and 600 mg/L of Al2(SO4)3. The study showed a promising approach of new isolated strain to produce high concentration EPS in sludge with high flocculation activity as well as good settlin

Characterization of Extracellular Polymeric Substances (Eps) Produced by \u3ci\u3eCloacibacterium normanense\u3c/i\u3e Isolated from Wastewater Sludge for Sludge Settling and Dewatering

In this study, extracellular polymeric substances (EPSs) producing strain was isolated from municipal wastewater sludge (MWWS). Growth profile and the EPS production by Cloacibacterium normanense using wastewater sludge as raw material in shake flask fermentation for 96 h were investigated. The highest concentration of S-EPS (13.0 ± 0.8 g/L) and C-EPS (0.3 ± 0.1 g/L) were attained at 48 h of fermentation. S-EPS revealed higher flocculation activity (94.2%) and dewaterability (59.9%) than other types of EPS in kaolin suspension. The dewaterability of MWWS with 2 g suspended solids (SS)/L was improved by 37.6% using 0.02 ± 0.01 g/L of S-EPS and 600 mg/L of Al2(SO4)3. The study showed a promising approach of new isolated strain to produce high concentration EPS in sludge with high flocculation activity as well as good settlin

Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis

Sleep-related eating disorder (SRED) is a parasomnia with recurrent, involuntary, amnestic eating episodes during sleep. There is growing evidence of the association between SRED and medications. Therefore, we aimed to rank drugs showing the strongest association. VigiBase® (WHO pharmacovigilance database) was queried for all reports of “Sleep-related eating disorder”. Disproportionality analysis relied on the Reporting Odds Ratio, with its 95% Confidence Interval (CI), and the Information Component. Our VigiBase® query yielded 676 cases of drug-associated SRED. Reports mostly involved zolpidem (243, 35.9%), sodium oxybate (185, 27.4%), and quetiapine (97, 14.3%). Significant disproportionality was found for 35 medications, including zolpidem (387.6; 95%CI 331.2–453.7), sodium oxybate (204.2; 95%CI 172.4–241.8), suvorexant (67.3; 95%CI 38.0–119.2), quetiapine (53.3; 95%CI 43.0–66.1), and several psychostimulants and serotonin-norepinephrine reuptake inhibitors (SNRIs). Patients treated with nonbenzodiazepines or SNRIs were significantly older (mean age: 49.0 vs. 37.5; p < 0.001) and their SRED were more likely to be serious (62.6% vs. 51.4%; p = 0.014) than patients treated with sodium oxybate or psychostimulants. Psychotropic drugs are involved in almost all reports. In patients with SRED, an iatrogenic trigger should be searched for